These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 54923)

  • 21. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complement: activation, consequences, and control.
    James K
    Am J Med Technol; 1982 Sep; 48(9):735-42. PubMed ID: 6215861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of C1s, C1r and properdin in the initiation of the C3b-dependent feedback mechanism of the complement system.
    Johnson U
    Acta Pathol Microbiol Scand C; 1978 Apr; 86(2):73-8. PubMed ID: 696332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The alternative pathway of complement activation.
    Götze O; Müller-Eberhard HJ
    Adv Immunol; 1976; 24():1-35. PubMed ID: 798473
    [No Abstract]   [Full Text] [Related]  

  • 27. The interaction of glycoprotein C of herpes simplex virus types 1 and 2 with the alternative complement pathway.
    Hung SL; Peng C; Kostavasili I; Friedman HM; Lambris JD; Eisenberg RJ; Cohen GH
    Virology; 1994 Sep; 203(2):299-312. PubMed ID: 8053154
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The properdin pathway: mechanisms of complement activation and analogies to the classical pathway.
    Fearon DT; Austen KF; Ruddy S
    Rheumatology; 1975; 6():2-16. PubMed ID: 1105744
    [No Abstract]   [Full Text] [Related]  

  • 29. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction of zymosan and of activated properdin with factor D-depleted guinea pig serum: implications for the mechanism of initial C3 cleavage via the alternative complement pathway.
    Brade V; Bentley C; Bitter-Suermann D; Hadding U
    Z Immunitatsforsch Immunobiol; 1977 Feb; 152(5):402-14. PubMed ID: 556571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative pathway complement activation in rheumatoid arthritis.
    El-Ghobarey A; Whaley K
    J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
    Farries TC; Lachmann PJ; Harrison RA
    Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Binding of properdin to solid-phase immune complexes: critical role of the classical activation pathway of complement.
    Junker A; Baatrup G; Svehag SE; Wang P; Holmström E; Sturfelt G; Sjöholm AG
    Scand J Immunol; 1998 May; 47(5):481-6. PubMed ID: 9627133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Binding of activated properdin to untreated erythrocytes: a new function of activated properdin.
    Konno T; Hirai H; Tamura N
    Immunology; 1978 Feb; 34(2):207-15. PubMed ID: 627406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.
    Vogt W; Schmidt G; Lynen R; Dieminger L
    J Immunol; 1975 Feb; 114(2 Pt 1):671-7. PubMed ID: 804510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement fixation by solid phase immune complexes. Reduced capacity in SLE sera.
    Baatrup G; Jonsson H; Sjöholm A; Sturfelt G; Svehag SE
    J Clin Lab Immunol; 1988 Jun; 26(2):73-9. PubMed ID: 3264027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B.
    Ruddy S; Austen KF; Goetzl EJ
    J Clin Invest; 1975 Mar; 55(3):587-92. PubMed ID: 1167871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Babesia rodhaini: requirement of complement for penetration of human erythrocytes.
    Chapman WE; Ward PA
    Science; 1977 Apr; 196(4285):67-70. PubMed ID: 841340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of the complement and properdin systems in rheumatoid arthritis.
    Ruddy S; Austen KF
    Ann N Y Acad Sci; 1975 Jun; 256():96-104. PubMed ID: 1099964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.